• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Molecular Diagnostics Market & Future Forecast to 2017 Overview Product Image

Global Molecular Diagnostics Market & Future Forecast to 2017 Overview

  • ID: 2516247
  • April 2013
  • Region: Global
  • 158 Pages
  • Renub Research

The global molecular diagnostics market is witnessing a period of profound growth. The growth is coming from different regions and markets. The next five years will witness significant developments in molecular diagnostics such as automation, as well as introduction of a wide range of new products. Molecular Diagnostics involves multiple technologies to identify genetic variations in individual patients. These technologies include PCR, FISH, hybrid capture, sequencing and microarrays. The increase in the aging population and incidences of various chronic diseases are driving the demand of molecular diagnostics world over. The industry is getting a push from every side and many factors collectively are fuelling the growth in this industry. Growing with a CAGR of 14.64 percent global molecular diagnostics market is expected to double its market size in 2017 from the market of 2012.

Molecular Diagnostics Market - Application Segment Analysis

- The infectious disease testing is the leading application in Molecular Diagnostic. It is likely to hold XXXX% share in 2017.

- Molecular oncology tests have emerged as a second significant rapidly growing market segment. Genetic READ MORE >

Note: Product cover images may vary from those shown

Table of Contents

1. Executive Summary

2. Molecular Diagnostics Market & Forecast – (2010 – 2017)

3. Molecular Diagnostics Market Share – (2010 – 2017)
3.1 Molecular Diagnostics Market Share & Forecast – Application Wise
3.2 Molecular Diagnostics Market Share & Forecast – Technology Wise
3.3 Molecular Diagnostics Market Share & Forecast – Region Wise
3.4 Molecular Diagnostics Market Share & Forecast – Company Wise

4. Molecular Diagnostics Market (Application Segment) – (2010 – 2017)
4.1 Infectious Disease Testing Market & Forecast
4.1.1 Virology (HIV, HCV, HBV) Testing Market & Forecast
4.1.2 Health – Associated Infections (HAI) Testing Market & Forecast
4.1.3 HPV Testing Market & Forecast
4.1.4 Critical Care Infectious Testing Market & Forecast
4.2 Blood Screening Market & Forecast
4.3 Genetic Testing Market & Forecast
4.4 Oncology Testing Market & Forecast
4.5 Tissue Typing (HLA Testing) Market & Forecast
4.6 Cardiovascular Disease Testing Market & Forecast
4.7 Neurological Disorders Testing Market & Forecast
4.8 Food Pathogen Detection Testing Market & Forecast
4.9 Miscellaneous Testing Market & Forecast

5. Molecular Diagnostics Market (Technologies Segment) – (2010 – 2017)
5.1 PCR Based Test Market & Forecast
5.2 PCR Related Technologies Market & Forecast
5.3 Non-PCR Test Market & Forecast
5.4 Fish & Innovations Testing Market (Fluorescent in-situ hybridization) & Forecast
5.5 Biochips/Microarrays Market & Forecast
5.6 Biosensors Market & Forecast
5.7 Molecular Imaging Market & Forecast
5.8 Other Technologies Market & Forecast

6. Geographical Distribution – Molecular Diagnostics Market – (2008 – 2017)
6.1 United States Molecular Diagnostics Market & Forecast
6.2 Europe Molecular Diagnostics Market & Forecast
6.3 China Molecular Diagnostics Market & Forecast
6.4 Japan Molecular Diagnostics Market & Forecast
6.5 India Molecular Diagnostics Market & Forecast
6.6 Brazil Molecular Diagnostics Market & Forecast
6.7 Mexico Molecular Diagnostics Market & Forecast
6.8 South Korea Molecular Diagnostics Market & Forecast
6.9 Rest of World Molecular Diagnostics Market & Forecast

7. Molecular Diagnostics Market (Company Wise) – (2010 – 2017)
7.1 Roche Molecular Diagnostics Market & Forecast
7.2 Abbott Molecular Diagnostics Market & Forecast
7.3 Myriad Genetics Molecular Diagnostics Market & Forecast
7.4 Qiagen Molecular Diagnostics Market & Forecast
7.5 BioMérieux Molecular Diagnostics Market & Forecast
7.6 Other Companies Molecular Diagnostics Market & Forecast

8. Molecular Diagnostics and Personalized Medicine
8.1 Road to Personalized Medicine
8.1.1 Historical perspective: HIV & Oncology
8.1.2 Other Applications: Met & Unmet Therapy Areas

8.2 Molecular Diagnostics Technologies
8.2.1 Expression Profiling - RNA & Pharmacogenomics
8.2.2 Expression Profiling - Proteins & Pharmacoproteomics
8.2.3 DNA Sequence Profiling - Pharmacogenetic & SNP Analysis
8.2.4 DNA Sequence Profiling - High-Throughput Sequencing

8.3 Molecular Diagnostics and Personalized Medicine: Value-Assessed Opportunities for Multiple Stakeholders Values, Needs & Expectations

8.4 Regulatory Authorities

8.5 Molecular Diagnostics as Companion Diagnostics: Value-Driven Adoption
8.5.1 Behavioral Impact
8.5.2 Economic Impact (Value-Based vs. Cost-Plus Pricing)

9. Molecular Diagnostics Clinical Trial Statement
9.1 Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples
9.2 Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase (ALK) Translocation
9.3 A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus
9.4 Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
9.5 A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test
9.6 Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma
9.7 Biopsies of Cancer Patients for Tumor Molecular Characterization
9.8 Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
9.9 Collection of Tissue Samples for Cancer Research
9.10 Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
9.11 Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia
9.12 Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
9.13 Congenital Muscle Disease Study of Patient and Family Reported Medical Information
9.14 Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates
9.15 Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
9.16 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib
9.17 Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile
9.18 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients
9.19 Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
9.20 Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

10. Molecular Diagnostics Market – Drivers
10.1 Various Developments in the Molecular Diagnostics Landscape
10.2 Increasing Investment in Genomics & Proteomics Research
10.3 Technological Advances in Molecular Diagnostics
10.4 Increasing Acceptance of the Personalized Medicine
10.5 Growing Molecular Diagnostics for Food Safety

11. Molecular Diagnostics Market – Challenges
11.1 Regulatory Issues
11.2 Various Factors Slowing Growth of Molecular Diagnostics
11.3 Reimbursement Capabilities
11.4 Quality Checkpoints, Awareness & Acceptance

List of Figures:

Figure 2 1: Global – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 2 2: Global – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017

Figure 3 1: Global Molecular Diagnostics – Application Wise Market Share (Percent), 2010 – 2012
Figure 3 2: Global Molecular Diagnostics – Forecast for Application Wise Market Share (Percent), 2013 – 2017
Figure 3 3: Global Molecular Diagnostics – Technology Wise Market Share (Percent), 2010 – 2012
Figure 3 4: Global Molecular Diagnostics – Forecast for Technology Wise Market Share (Percent), 2013 – 2017
Figure 3 5: Global Molecular Diagnostics – Region Wise Market Share (Percent), 2010 – 2012
Figure 3 6: Global Molecular Diagnostics – Forecast for Region Wise Market Share (Percent), 2013 – 2017

Figure 4 1: Global – Infectious Disease Testing Market (Million US$), 2010 – 2012
Figure 4 2: Global – Forecast for Infectious Disease Testing Market (Million US$), 2013 – 2017
Figure 4 3: Global – Virology Testing Market (Million US$), 2010 – 2012
Figure 4 4: Global – Forecast for Virology Testing Market (Million US$), 2013 – 2017
Figure 4 5: Global – HAI Testing Market (Million US$), 2010 – 2012
Figure 4 6: Global – Forecast for HAI Testing Market (Million US$), 2013 – 2017
Figure 4 7: Global – HPV Testing Market (Million US$), 2010 – 2012
Figure 4 8: Global – Forecast for HPV Testing Market (Million US$), 2013 – 2017
Figure 4 9: Global – Critical Care Infectious Testing Market (Million US$), 2008 – 2012
Figure 4 10: Global – Forecast for Critical Care Infectious Testing Market (Million US$), 2013 – 2017
Figure 4 11: Global – Blood Screening Market (Million US$), 2007 – 2012
Figure 4 12: Global – Forecast for Blood Screening Market (Million US$), 2013 – 2017
Figure 4 13: Global – Genetic Testing Market (Million US$), 2010 – 2012
Figure 4 14: Global – Forecast for Genetic Testing Market (Million US$), 2013 – 2017
Figure 4 15: Global – Oncology Market (Million US$), 2010 – 2012
Figure 4 16: Global – Forecast for Oncology Market (Million US$), 2013 – 2017
Figure 4 17: Global – Tissue Typing Market (Million US$), 2008 – 2012
Figure 4 18: Global – Forecast for Tissue Typing Market (Million US$), 2013 – 2017
Figure 4 19: Global – Cardiovascular Disease Testing Market (Million US$), 2010 – 2012
Figure 4 20: Global – Forecast for Cardiovascular Disease Testing Market (Million US$), 2013 – 2017
Figure 4 21: Global – Neurological Disorders Testing Market (Million US$), 2010 – 2012
Figure 4 22: Global – Forecast for Neurological Disorders Testing Market (Million US$), 2013 – 2017
Figure 4 23: Global – Food Pathogen Detection Testing Market (Million US$), 2010 – 2012
Figure 4 24: Global – Forecast for Food Pathogen Detection Testing Market (Million US$), 2013 – 2017
Figure 4 25: Global – Miscellaneous Testing Market (Million US$), 2010 – 2012
Figure 4 26: Global – Forecast for Miscellaneous Testing Market (Million US$), 2013 – 2017

Figure 5 1: Global – PCR Based Test Market (Million US$), 2010 – 2012
Figure 5 2: Global – Forecast for PCR Based Test Market (Million US$), 2013 – 2017
Figure 5 3: Global – PCR Related Technologies Market (Million US$), 2010 – 2012
Figure 5 4: Global – Forecast for PCR Related Technologies Market (Million US$), 2013 – 2017
Figure 5 5: Global – Non-PCR Test Market (Million US$), 2010 – 2012
Figure 5 6: Global – Forecast for Non-PCR Test Market (Million US$), 2013 – 2017
Figure 5 7: Global – Fish & Innovations Market (Million US$), 2010 – 2012
Figure 5 8: Global – Forecast for Fish & Innovations Market (Million US$), 2013 – 2017
Figure 5 9: Global – Biochips/ Microarrays Market (Million US$), 2010 – 2012
Figure 5 10: Global – Forecast for Biochips/Micrroarrays Market (Million US$), 2013 – 2017
Figure 5 11: Global – Biosensors Market (Million US$), 2010 – 2012
Figure 5 12: Global – Forecast for Biosensors Market (Million US$), 2013 – 2017
Figure 5 13: Global – Molecular Imaging Market (Million US$), 2010 – 2012
Figure 5 14: Global – Forecast for Molecular Imaging Market (Million US$), 2013 – 2017
Figure 5 15: Global – Other Technologies Market (Million US$), 2010 – 2012
Figure 5 16: Global – Forecast for Other Technologies Market (Million US$), 2012 – 2017

Figure 6 1: US – Molecular Diagnostics Market (Million US$), 2002 – 2012
Figure 6 2: US – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 3: Europe – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 6 4: Europe – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 5: China – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 6 6: China – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 7: Japan – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 6 8: Japan – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 9: India – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 6 10: India – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 11: Brazil – Molecular Diagnostics Market (Million US$), 2007 – 2012
Figure 6 12: Brazil – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 13: Mexico – Molecular Diagnostics Market (Million US$), 2007 – 2012
Figure 6 14: Mexico – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 15: South Korea – Molecular Diagnostics Market (Million US$), 2005 – 2012
Figure 6 16: South Korea – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017
Figure 6 17: Rest of World – Molecular Diagnostics Market (Million US$), 2010 – 2012
Figure 6 18: Rest of World – Forecast for Molecular Diagnostics Market (Million US$), 2013 – 2017

Figure 7 1: Roche – Molecular Diagnostics Sales (Million US$), 2008 – 2012
Figure 7 2: Roche – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017
Figure 7 3: Abbott – Molecular Diagnostics Sales (Million US$), 2010 – 2012
Figure 7 4: Abbott – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017
Figure 7 5: Myriad Genetics – Molecular Diagnostics Sales (Million US$), 2007 – 2012
Figure 7 6: Myriad Genetics – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017
Figure 7 7: Qiagen – Molecular Diagnostics Sales (Million US$), 2009 – 2012
Figure 7 8: Qiagen – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017
Figure 7 9: BioMérieux – Molecular Diagnostics Sales (Million US$), 2010 – 2012
Figure 7 10: BioMérieux – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017
Figure 7 11: Other Companies – Molecular Diagnostics Sales (Million US$), 2010 – 2012
Figure 7 12: Other Companies – Forecast for Molecular Diagnostics Sales (Million US$), 2013 – 2017

Figure 8 1: A Healthcare ‘Value-Net'

List of Tables:

Table 3 1: Global Molecular Diagnostics – Company Wise Market Share (Percent), 2010 – 2012
Table 3 2: Global Molecular Diagnostics – Forecast for Company Wise Market Share (Percent), 2013 – 2017

Table 8 1: Molecular Platforms for Companion Diagnostics

Table 9 1: Detecting Respiratory Viruses in Upper and Lower Respiratory Tract Samples – Clinical Trials, 2012
Table 9 2: Crizotinib Efficacy in Non-Small Cell Lung Cancer Patients with Anaplastic Lymphoma Kinase Translocation – Clinical Trials, 2012
Table 9 3: A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus – Clinical Trials, 2012
Table 9 4: Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler – Clinical Trials, 2012
Table 9 5: A Two Arm, Multi-Centre Clinical Evaluation of the xTAG Respiratory Viral Panel v3 Test – Clinical Trials, 2013
Table 9 6: Collecting and Storing Tissue Samples from Patients with Rare or Cutaneous Non-Hodgkin Lymphoma – Clinical Trials, 2012
Table 9 7: Biopsies of Cancer Patients for Tumor Molecular Characterization – Clinical Trails, 2012
Table 9 8: Daptomycin versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia – Clinical Trials, 2013
Table 9 9: Collection of Tissue Samples for Cancer Research – Clinical Trials, 2012
Table 9 10: Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma – Clinical Trials, 2012
Table 9 11: Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia – Clinical Trials, 2012
Table 9 12: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy, 2013
Table 9 13: Congenital Muscle Disease Study of Patient and Family Reported Medical Information – Clinical Trials, 2013
Table 9 14: Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer from Fine Needle Aspirates – Clinical Trials, 2013
Table 9 15: Extending Molecular Responses with Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients in Chronic Phase – Clinical Trials, 2012
Table 9 16: CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib – Clinical Trial, 2013
Table 9 17: Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile – Clinical Trials, 2013
Table 9 18: Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients – Clinical Trials, 2012
Table 9 19: Radotinib versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients – Clinical Trials, 2012
Table 9 20: Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) – Clinical Trials, 2012

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos